Literature DB >> 26381394

Performance of processes of care and outcomes in patients with Staphylococcus aureus bacteremia.

Rossana Rosa1,2, Andrew Wawrzyniak3, Maroun Sfeir1, Laura Smith4, Lilian M Abbo2.   

Abstract

BACKGROUND: Staphylococcus aureus bacteremia (SAB) is associated with significant morbidity and mortality in hospitalized adults.
OBJECTIVE: We aimed to identify current practice patterns in the management of SAB, and to evaluate their association with clinical outcomes.
DESIGN: Retrospective cohort study.
SETTING: A 1558-bed tertiary care teaching hospital. PATIENTS: Adult patients hospitalized between January 1, 2012 through April 30, 2013, who had at least 1 positive blood culture with S aureus. INTERVENTION: None MEASUREMENTS: Electronic medical records were reviewed and the processes of care in the management of SAB were identified. The main outcome was clinical failure, defined as a composite endpoint of in-hospital mortality and persistent bacteremia.
RESULTS: Two hundred fifty episodes of SAB occurred in 241 patients, and 78 (32.4%) had clinical failure. Processes of care that impacted the risk of clinical failure included: timing of follow-up blood cultures (delays of >4 days had a relative risk [RR] of 6.6; 95% confidence interval [CI]: 2.1-20.5; P = 0.001), consultation with infectious diseases specialist within 6 days from diagnosis of SAB (RR: 0.3; 95% CI: 0.1-0.9; P = 0.03), and use of β-lactams in patients with methicillin-susceptible S aureus bacteremia (RR: 0.1; 95% CI: 0.04-0.5; P = 0.002).
CONCLUSIONS: The processes of care identified in our study could serve as quality and patient safety indicators for the management of SAB.
© 2015 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26381394     DOI: 10.1002/jhm.2479

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  1 in total

1.  Development of quality indicators for the management of Staphylococcus aureus bacteraemia.

Authors:  Jaap Ten Oever; Joëll L Jansen; Thomas W van der Vaart; Jeroen A Schouten; Marlies E J L Hulscher; Annelies Verbon
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.